Skip to main content

If you're experiencing a crisis, call 988 to reach someone at the Suicide & Crisis Lifeline immediately.

Start a Search

Spero Health - Danville

Contact Information

Facility Hours

Monday: 08:00 am - 04:30 pm

Tuesday: 08:00 am - 04:30 pm

Wednesday: 08:00 am - 04:30 pm

Thursday: 08:00 am - 04:30 pm

Friday: 08:00 am - 04:30 pm

Hotline Numbers

(877) 787-7376

Intake Numbers

(877) 787-7376
Loading...

About

Spero Health, Inc., is an integrated healthcare services organization specializing in local and affordable outpatient care for individuals suffering from substance use disorders with a mission to “Save Lives, Instill Hope, and Restore Relationships.” Spero Health utilizes an innovative evidence-based integrated care model that combines both physical and behavioral healthcare services under one roof to treat the whole patient. This integrated care model combines physician services (including medication-assisted treatment), behavioral health counseling, recovery support services, medication management and patient and family education. Its community-based approach to treatment allows patients to continue working and caring for their families as they overcome addiction. Based in Nashville, Tenn. and privately held by Heritage Group, Health Velocity Capital, South Central, Inc. and Frist Cressey Ventures, Spero Health operates over 95 outpatient clinics located throughout Ohio, West Virginia, Kentucky, Indiana, Virginia and Tennessee. Spero Health is one of the largest office-based opioid treatment providers in the country and is in-network with Medicaid and most commercial insurance plans. For more information about Spero Health, please visit www.sperohealth.com

Treatment Services

Substance Use Disorder Treatment

Accreditation and Licensure

AODE

|

BHSO

|

CARF

Information

Accepting Patients

Not Accepting Patients

Treatment Type

    • Outpatient
    • Intensive Outpatient
    • Medication for Opioid Use Disorder
      • Buprenorphine / Suboxone
      • Zubsolv
      • Vivitrol / Naltrexone

Facility Type

  • Private

Treatment Services

  • Case Management

Accepted Forms Of Payment

  • Medicaid
    • Aetna
    • Anthem
    • Humana
    • Passport
    • WellCare
    • United Healthcare Community Plan
  • Medicare
  • Private Insurance
  • Self-Pay
  • Military Insurance / Tri-Care

Additional Services

  • Employment Assistance
  • Housing Assistance
  • Peer Support / Peer Recovery Program
  • Hepatitis Education
  • HIV/AIDS Education
  • Involuntary Treatment (Casey's Law)

Population Served

  • Age
    • Adult
  • Gender
    • Female
    • Male
    • Transgender Female
    • Transgender Male
    • Non-binary
    • Intersex
  • LGBTQ+
  • Pregnant / Postpartum
  • First Responders
  • Veterans/Military
  • Health Care Professionals
  • Teachers
  • Preferred Language
    • English
  • Disabled
  • Current Mental Health Diagnosis
  • Currently Receiving Medications for Opioid Use Disorder (MOUD)
  • Correctional/Legal

Policies

Tobacco Policy

  • Smoking
    • Allowed
  • Dipping
    • Allowed
  • E cigarettes
    • Allowed
  • Smoking cessation products
    • Not Allowed
  • Smoking Cessation Aids Available at Facility

Referral / Admission

  • Admission criteria
    • Potential patients must meet the stated criteria in order to be admitted for addiction treatment services. 1. Patient must be at least 18 years of age. 2. Current use of opiates or alcohol. Current is defined as use within 30 days prior to proposed admission date. This requirement may be waived if patient: a) Is currently pregnant b) Is being transferred/referred from another addiction treatment program c) Has recently been released from the hospital (last 30 days) d) Has recently been released from incarceration (last 30 days) e) Is a patient who was recently discharged from services and is at risk of relapse (last 30 days) f) Is only seeking treatment with naltrexone/Vivitrol due to concern about relapsing. Admission and treatment with naltrexone/Vivitrol can be provided as a means to avoid/minimize risk of relapse to alcohol or opiates. Buprenorphine cannot be provided unless there is current use of opiates. 3. Patient must meet the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria for opiate dependence (treatment with buprenorphine or naltrexone/Vivitrol) or alcohol dependence (treatment with naltrexone/Vivitrol) or equivalent diagnosis per updated versions of the DSM. 4. Patient must meet the criteria for office-based opiate treatment (OBOT). 5. Patient must be medically and psychiatrically stable enough to fully participate in outpatient treatment. If patient is pregnant, see policy Treating Protocols for Pregnant Women. 6. Patient must have the means and motivation to follow program rules and requirements, attendance, and medical/clinical recommendations. 7. Patient must be willing to give written consent for SelfRefind to communicate with and obtain any necessary medical records from other treatment providers. 8. Patients will not be denied admission solely due to their use psychotropic medications. A patient may be denied admission to the treatment program due to: 1. Exhibiting bizarre or violent behavior or ideation, or acute psychosis such that the person is dangerous to himself and/or others and who would be better treated in a higher level of care. 2. Current suicidal or homicidal ideation/plan that requires intervention in a higher level of care. 3. Having medical needs that interfere with treatment or cannot be stabilized on an outpatient basis. 4. Any patient who is denied admission will be provided information on other treatment options that are more appropriate.

Other Requirements / Policies

  • Prescription Medication Policy Details
    • Physicians will evaluate patients non-SelfRefind prescribed medication on a case by case basis
  • HIV Screening Offered
  • HIV Screening Required
  • Outside Prescriptions Allowed